Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

BIVALIRUDIN

BIVALIRUDIN

Standard Dose
250MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary

Approval overview BIVALIRUDIN is listed in Drugs@FDA under application 091468 (ANDA).

Marketing status: None (Tentative Approval) Active ingredient BIVALIRUDIN Form and strength INJECTABLE;INJECTION - 250MG/VIAL Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2017-02-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview BIVALIRUDIN is listed in Drugs@FDA under application 091468 (ANDA). Marketing status: None (Tentative Approval) Active ingredient BIVALIRUDIN Form and strength INJECTABLE;INJECTION - 250MG/VIAL Sponsor MYLAN LABS LTD Submission history Latest submission status date: 2017-02-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)

Interaction Notes

  • No interaction notes stored yet.